Company intelligence / Profile preview

ORIQL

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Oriql is a precision medicine biotechnology company focused on developing targeted therapies for oncology and rare genetic disorders. The company utilizes a proprietary platform to identify and validate specific molecular drivers of disease, enabling the design of highly selective small molecule therapeutics. By integrating advanced computational biology with deep biological insights, Oriql aims to address unmet medical needs in patient populations defined by specific genetic profiles. The company is currently in the pre-clinical stage, advancing a pipeline of programs toward investigative new drug (IND) filings.

Therapeutic areas: Rare DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on ORIQL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIQL.

Explore the full profile